Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Inflammatory Bowel Diseases|February 25, 2009
Crohn's disease in a southern European country: Montreal classification and clinical activityFernando Magro, Francisco Portela, Paula Lago, et al.
Therapeutic Advances in Gastroenterology|September 14, 2019
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabFernando Magro, Susana Lopes, Marco Silva, et al.
Inflammatory Bowel Diseases|October 14, 2009
Ulcerative colitis in a Southern European country: a national perspectiveFrancisco Portela, Fernando Magro, Paula Lago, et al.
Therapeutic Advances in Gastroenterology|September 22, 2017
Clinical performance of an infliximab rapid quantification assayFernando Magro, Joana Afonso, Susana Lopes, et al.
Therapeutic Advances in Gastroenterology|November 3, 2016
Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assaysJoana Afonso, Susana Lopes, Raquel Gonçalves, et al.
Inflammatory Bowel Diseases|January 21, 2017
Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling OutcomesFernando Magro, Cláudia C Dias, Rosa Coelho, et al.
Inflammatory Bowel Diseases|May 11, 2012
Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II)Cecília Durães, José C Machado, Francisco Portela, et al.
Journal of Crohn'S & Colitis|September 30, 2016
Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic InterventionsCláudia Camila Dias, Pedro Pereira Rodrigues, Rosa Coelho, et al.
Pageof 4